Core Viewpoint - The rapid transformation of Huajian Medical into a "new species" in the capital market is driven by its strategic actions, including a dual primary listing in the U.S. and the launch of innovative financial products, resulting in a significant increase in market capitalization from 3.6 billion to nearly 8 billion HKD within a month [1][4][9]. Group 1: Strategic Actions - On July 14, Huajian Medical announced its plan for a dual primary listing on NASDAQ to expand its international shareholder base [4]. - Three days later, the company introduced the world's first medical innovation drug RWA exchange, IVDNewCo Exchange, along with a stablecoin, IVDDollar [5]. - The establishment of a wholly-owned subsidiary, IVD GROUP INC., in New York was announced on July 20, alongside applications for stablecoin licenses to the SEC and CFTC [5]. - From July 23 to 28, the company executed three high-priced share buybacks, spending over 6.13 million HKD to repurchase 1.721 million shares, with average transaction prices rising from 3.16 HKD to 3.67 HKD [5]. - On July 29, the subsidiary Weishida secured a multi-hundred million HKD revolving loan led by East Asia Bank, indicating strong backing from financial institutions [5]. - A brand strategy upgrade was announced on July 30, featuring a new logo symbolizing "innovation-validation-development" [5]. - The same day, a partnership with BGI Group was established to create an innovative drug intellectual property tokenization fund, enhancing the integration of medical assets on the blockchain [5]. Group 2: Market Dynamics - The innovative drug industry is experiencing a value reassessment, with 48 out of 93 new drugs approved by the drug regulatory agency in 2024 being innovative drugs, and the scale of outbound licensing transactions soaring to 51.9 billion USD [10]. - As of July 29, the China Securities Hong Kong Stock Connect Innovative Drug Index has risen over 124% from its low point at the beginning of the year, with 16 innovative drug funds doubling their returns [10]. - The global regulatory landscape for stablecoins is evolving, with the U.S. "Genius Act" and Hong Kong's stablecoin regulations coming into effect, establishing a compliance network across Europe, the U.S., and Asia [10]. Group 3: Valuation Revolution - Following the dual listing announcement on July 14, Huajian Medical's stock price surged, with a cumulative increase of 75.1% from July 14 to 21, and a peak price of 4.99 HKD per share on July 31, pushing its market capitalization to 8 billion HKD [11]. - The company's valuation is shifting from traditional IVD distribution metrics to a premium associated with its new role as a medical RWA exchange [11]. Group 4: Future Outlook - The global RWA market is projected to reach 16.1 trillion USD by 2030, with stablecoin transaction volumes expected to surpass Visa's by 2024 [12]. - Huajian Medical aims to create a closed-loop ecosystem, capturing innovative drug pipelines, tokenizing RWA, and facilitating payments through its stablecoin [12]. - The company aspires to become a leader in the medical RWA sector, akin to NASDAQ for asset tokenization, Visa for stablecoin payments, and Apple for integrating technology and capital [14].
华检医疗(01931)的“疯狂7月”